{"filing":{"accession_number":"0000899923-26-000094","cik":"0000899923","ticker":"MYGN","company_name":"MYRIAD GENETICS INC","form":"8-K","filing_date":"2026-10-20","report_date":"2026-10-19","primary_document":"mygn-20261019.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992326000094/mygn-20261019.htm"},"events":[{"id":36304,"run_id":33471,"accession_number":"0000899923-26-000094","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Myriad Genetics entered into a definitive Asset Purchase Agreement with Laboratory Corporation of America to sell its prenatal health testing business for $210 million in cash plus inventory value. This material disposition of a business unit is expected to strengthen Myriad's balance sheet and support strategic priorities.","company_name":"MYRIAD GENETICS INC","ticker":"MYGN","filing_date":"2026-10-20","form":"8-K","submitted_at":null,"items":[{"id":40672,"accession_number":"0000899923-26-000094","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Myriad Genetics entered into a definitive Asset Purchase Agreement with Laboratory Corporation of America to sell its prenatal health testing business for $210 million in cash plus inventory value. This is a material disposition of a business unit disclosed under Item 1.01, representing a significant divestiture that will affect Myriad's revenue, profitability, and balance sheet, as explicitly stated in the press release and management commentary.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:37:39.545024+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40673,"accession_number":"0000899923-26-000094","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Myriad Genetics has entered into a definitive agreement to sell its Prenatal Health testing business to Labcorp for $210 million in cash plus inventory value. This is a material disposition of a business unit that the company expects to strengthen its balance sheet and support strategic priorities. The transaction is a clear M\u0026A activity—specifically a divestiture—that would materially affect a reasonable investor's assessment of the registrant's portfolio and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:37:39.545024+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40672,"accession_number":"0000899923-26-000094","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Myriad Genetics entered into a definitive Asset Purchase Agreement with Laboratory Corporation of America to sell its prenatal health testing business for $210 million in cash plus inventory value. This is a material disposition of a business unit disclosed under Item 1.01, representing a significant divestiture that will affect Myriad's revenue, profitability, and balance sheet, as explicitly stated in the press release and management commentary.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:37:39.545024+00:00","company_name":"MYRIAD GENETICS INC","ticker":"MYGN","filing_date":"2026-10-20"},{"id":40673,"accession_number":"0000899923-26-000094","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Myriad Genetics has entered into a definitive agreement to sell its Prenatal Health testing business to Labcorp for $210 million in cash plus inventory value. This is a material disposition of a business unit that the company expects to strengthen its balance sheet and support strategic priorities. The transaction is a clear M\u0026A activity—specifically a divestiture—that would materially affect a reasonable investor's assessment of the registrant's portfolio and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:37:39.545024+00:00","company_name":"MYRIAD GENETICS INC","ticker":"MYGN","filing_date":"2026-10-20"}]}